Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study

Janna Schoenmaekers, Paul Hofman, Gerben Bootsma, Marcel Westenend, Machiel de Booij, Wendy Schreurs, Ruud Houben, Dirk De Ruysscher, Anne-Marie Dingemans, Lizza E. L. Hendriks*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Web of Science)
177 Downloads (Pure)

Abstract

Introduction: Non-small-cell lung cancer (NSCLC) guidelines advise to screen stage III NSCLC patients for brain metastases (BMs), preferably by magnetic resonance imaging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced-computed tomography (dCE-CT), which can be incorporated in the staging (18)Fluodeoxoglucose-positron emission tomography ((18)FDG-PET-CE-CT). In daily practice, often a dCE-CT is performed instead of a MRI. The aim of the current study is to evaluate the additive value of MRI after dCE-CT, incorporated in the 18 FDG-PET-CE-CT.

Patients and methods: It is an observational prospective multicentre study (NTR3628). Inclusion criteria included stage III NSCLC patients with a dCE-CT of the brain incorporated in the (18)FDG-PET and an additional MRI of the brain. Primary end-point is percentage of patients with BM on MRI without suspect lesions on dCE-CT. Secondary end-points are percentage of patients with BM on dCE-CT and percentage of patients with BM

Results: Sixteen (7%) patients with extracranial stage III had BM on dCE-CT and were excluded. One hundred forty-nine patients were enrolled. 7/149 (4.7%) had BM on MRI without suspect lesions on dCE-CT. One hundred eighteen patients had a follow-up of at least 1 year (four with BM on baseline MRI); eight of the remaining 114 (7%) patients developed BM

Conclusion: Although in 7% of otherwise stage III NSCLC patients, BMs were detected on staging dCE-CT, MRI brain detected BMs in an additional 4.7%, which we consider clinically relevant. Within 1 year after a negative staging MRI, 7% developed BM. (C) 2019 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)88-96
Number of pages9
JournalEuropean Journal of Cancer
Volume115
DOIs
Publication statusPublished - Jul 2019

Keywords

  • NSCLC
  • Screening
  • Brain metastases
  • Magnetic resonance imaging
  • Computed tomography
  • CEREBRAL METASTASES
  • PHASE-III
  • FDG-PET
  • DIAGNOSIS
  • CHEMOTHERAPY
  • CT
  • CHEMORADIOTHERAPY
  • CHEMORADIATION
  • PROGNOSIS
  • ACCURACY

Cite this